Lesterhuis et al. compared the genomic profile of regressing and non-regressing tumours following anti-CTLA4 immunotherapy in a dichotomously-responding mesothelioma model, where approximately 20% of mice responded to therapy [69]. This evidence concerns the gene CTLA4 and mesothelioma.